Computational Molecular Biology 2016, Vol.6, No.1, 1-20
14
Anchoori R.K., Harikumar K.B., Batchu V.R., Aggarwal B.B., and Khan, S.R., 2010, Inhibition of IkB kinase and NF-κB by a novel synthetic compound SK.
Bioorganic and Medicinal Chemistry, 18(1): 229-235.
Aringer M., and Smolen J S., 2008, The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Research and Therapy, 10(1): 202.
Ashall L., Horton C.A., Nelson D.E., Paszek P., Harper C.V, Sillitoe K., and Ryan S., 2009, Pulsatile stimulation determines timing and specificity of NF- kappa
B-dependent transcription, Science, 324(5924): 242-246.
Baltimore D., 2009, Discovering NFκ B, Cold Spring Harb Perspect Biol., 1(1):a000026.
Basak S., Kim H., Kearns J.D., Tergaonkar V., O’Dea E., Werner S.L., and Hoffmann A., 2007, AFourth IκB Protein within the NF-κB Signaling Module. Cell,
128(2), 369-381.
Beasley S.A., Hristova V.A., and Shaw G.S., 2007, Structure of the Parkin in-between-ring domain provides insights for E3-ligase dysfunction in autosomal
recessive Parkinson’s disease, Proc Natl Acad Sci U S A. 104(9): 3095-3100.
Berman H.M., 2008, The Protein Data Bank: a historical perspective. Acta Crystallographica Section A Foundations of Crystallography, 64(1): 88-95.
Bernassola F., Karin M., Ciechanover A., and Melino G., 2008, The HECT Family of E3 Ubiquitin Ligases : Multiple Players in Cancer Development. Cancer
Cell, 14(1):10-21.
Bluml S., Scheinecker C., Smolen J.S., and Redlich K., 2012, Targeting TNF receptors in rheumatoid arthritis. International Immunology, 24(5): 275-281.
Calhoun E.S., Jones J.B., Ashfaq R., Adsay V., Baker S.J., Valentine V., and Kern S.E. 2003, BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) Mutations in
Distinct Subsets of Pancreatic Cancer. The American Journal of Pathology, 163(4): 1255-1260.
Campbell K.J., Chapman N.R., and Perkins N.D., 2001, UV stimulation induces nuclear factor kappaB (NF-kappaB) DNA-binding activity but not
transcriptional activation. Biochemical Society Transactions, 29(6): 688-91.
Cao D., Wang J., Zhou R., Li Y., Yu H., and Hou T., 2012, ADMET Evaluation in Drug Discovery. 11. PharmacoKinetics Knowledge Base (PKKB): A
Comprehensive Database of Pharmacokinetic and Toxic Properties for Drugs. Journal of Chemical Information and Modeling, 52(5): 1132–1137.
Cao Y., Wang C., Zhang X., Xing G., Lu K., Gu Y., and Zhang L., 2014, Selective small molecule compounds increase BMP-2 responsiveness by inhibiting
Smurf1-mediated Smad1/5 degradation. Scientific Reports, 4: 4965.
Carta F., Aggarwal M., Maresca A., Scozzafava A., Mckenna R., and Supuran C.T., 2012, Dithiocarbamates : a new class of carbonic anhydrase inhibitors .
Crystallographic and kinetic investigations, ChemComm., 48(13):1868-70.
Chan C.H., Morrow J.K., Li C.F., Gao Y., Jin G., Moten A., and Lin H.K., 2013, Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem
cell traits and cancer progression. Cell, 154(3): 556–68.
Chan W.M., Mak M.C., Fung T.K., Lau A., Siu W.Y., and Poon R.Y.C., 2006, Ubiquitination of p53 at multiple sites in the DNA-binding domain. Molecular
Cancer Research : MCR, 4(1): 15–25.
Chang Y.S., Graves B., Guerlavais V., Tovar C., Packman K., To K., and Sawyer T.K., 2013, Stapled α − helical peptide drug development : A potent dual
inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U.S.A.,
110(36):E3445-54.
Chaplain M.A.J., 2011, Multiscale mathematical modelling in biology and medicine. IMA Journal ofApplied Mathematics, 76(3): 371–388.
Chen D., Frezza M., Schmitt S., Kanwar J., and Dou Q.P., 2011, Bortezomib as the first proteasome inhibitor anticancer drug: current status and future
perspectives. Current Cancer Drug Targets, 11(3): 239–53.
Cheng T., Li Q., Zhou Z., Wang Y., and Bryant S.H., 2012, Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review. The AAPS
Journal, 14(1): 133-141.
Cheong R., Hoffmann A., and Levchenko A., 2008, Understanding NF-κB signaling via mathematical modeling, Mol Syst Biol.
4:192.
